¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"residual resistance"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • residual lumen
    ÀÜ·ù¼Ó°ø°£, ÀÜ·ù³»°­
  • residual nitrogen
    ÀÜ¿©Áú¼Ò
  • residual nucleus
    ÀÜ·ùÇÙ
  • residual paralysis
    ÈÄÀ¯¸¶ºñ
  • residual period
    ÀÜ·ù±â°£
  • residual proteinuria
    ÀÜ·ù´Ü¹é´¢
  • residual quotient
    ÀÜ·ùÁö¼ö, ÀܱâÀ²
  • residual radiation
    ÀÜ·ù¹æ»ç¼±
  • residual radioactivity
    ÀÜ·ù¹æ»ç´É
  • residual ray
    ÀÜ·ù¼±
  • residual schizophrenia
    ÀÜ·ùÁ¤½ÅºÐ¿­º´
  • residual shrinkage
    ÀÜ·ùÀ§Ãà
  • residual spray
    ÀÜ·ùºÐ¹«, ÀÜ·ù»ìÆ÷
  • residual stress
    ÀÜ·ù½ºÆ®·¹½º
  • residual transverse magnetization
    ÀÜ·ù°¡·ÎÃàÀÚ±âÈ­, ÀÜ·ùȾÃàÀÚ±âÈ­
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • residual immunity
    ÀÜ¿©¸é¿ª
  • residual latency
    ÀÜ·ùÀẹ
  • residual lumen
    ÀÜ¿©³»°­
  • residual transverse magnetization
    ÀÜ¿©È¾ÀÚ±âÈ­
  • residual volatile matter
    ÀÜ·ùÈֹ߼ººÐ
  • residual nitrogen
    ÀÜ¿©Áú¼Ò
  • residual nucleus
    ÀÜ·ùÇÙ
  • residual paralysis
    ÈÄÀ¯¸¶ºñ
  • residual period
    ÀÜ·ù±â°£
  • residual proteinuria
    ÀÜÀç´Ü¹é´¢
  • residual quotient
    ÀÜ·ùÁö¼ö, ÀܱâÀ²
  • residual
    ÀÜ·ù-
  • residual radiation
    ÀÜ·ù¹æ»ç¼±
  • residual radioactivity
    ÀÜ·ù¹æ»ç´É
  • residual ray
    ÀÜ·ù¼±
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • frictional resistance
    ¸¶ÂûÀúÇ×.
  • genetic resistance
    À¯Àü¼º ÀúÇ×.
  • heat resistance
    ³»¿­¼º(Ò±æðàõ).
  • heat resistance
    ³»¿­¼º(ËÀËçËÛ).
  • immunological resistance
    ¸é¿ªÀúÇ×.
  • index of resistance
    ÀúÇ×Áö¼ö(î½ù÷ò¦â¦).
  • insulin resistance
    Àν¶¸°ÀúÇ×¼º.
  • phage resistance
    ÆÄÁö³»¼º
  • plasmid, resistance (R)
    ³»¼ºÇö󽺹̵å, RÇö󽺹̵å
  • platinum resistance furnace
    ¹é±Ý·Î (ÛÜÐÝÖÓ).
  • pleiotropic resistance
    ´Ù¸é¹ßÇö¼º³»¼º
  • progressive resistance
    Á¡ÁõÀúÇ×(ïÂñòî½ù÷).
  • progressive resistance exercise
    Á¡ÁõÀúÇ׿(ïÂñòî½ù÷ê¡ÔÑ).
  • pulmonary flow resistance
    Æó±â·ùÀúÇ×(øËѨêüî½ù÷).
  • pulmonary vascular resistance
    ÆóÇ÷°üÀúÇ×(øËúìηî½ù÷), Æó¼øÈ¯ÀúÇ×.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • residual albuminuria
    ÀÜÁ¸´Ü¹é´¢(íÑðíÓ±ÛÜèñ).
  • residual antigen
    ÀÜ¿©Ç׿ø(íÑæ®ù÷ê«).
  • residual antigen
    ÀÜ·ùÇ׿ø, ÀÜÁ¸Ç׿ø
  • residual antigen
    ÀÜ¿©Ç׿ø(íÑæ®ù÷ê«).
  • residual astigmatism
    ÀÜ¿©³­½Ã
  • residual body
    ÀÜ·ùü(íÑ׺ô÷), ÀÜÁ¸Ã¼(íÑðíô÷)
  • residual body
    ÀÜ¿©¼Òü
  • residual carbon
    ÀÜ¿©Åº¼Ò(íÑæ®÷©áÈ).
  • residual chlorine
    ÀÜ·ù¿°¼Ò(ËöËôËçËÛ).
  • residual chromatin
    ¿°»öÁúÀÜ¿© (È£¿°±â¼º°ú¸³)
  • residual current
    ÀÜ·ùÀü·ù(íÑë§ï³êü).
  • residual cyst
    ÀÜ·ù³¶
  • residual cyst
    ÀÜ·ù³¶.
  • residual delirium
    ÀÜÀ缺 ¸Á»ó(íÑî¤àõØÍßÌ).
  • residual elengation
    ÀÜ·ù½ÅÀå(íÑë§ãßíå).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
TR recovery time; rectal temperature; repetition time; residual tuberculin; terminal repeat; tetrazoliu...
JVP [POMD P 49 - 52]
  1) Jugular Vein Pressure
  2) Jugular Venous Pulse
...
AR absolute risk; accounts receivable; achievement ratio; actinic reticuloid [syndrome]; active resista...
EPR early progressive resistance; electron paramagnetic resonance; electronic patient record; electrophr...
PR by way of the rectum [Lat. per rectum]; far point [of accommodation] [Lat. punctum remotum]; palindr...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
RVF Residual Volume Fraction
ROFA Residual oil fly ash
RRF Residual renal function
PVR post void residual
PVR post-void residual urine volume
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acoustic resistance
    À½Çâ ÀúÇ×
  • activated protein C resistance
    Ȱ¼ºÈ­ C ´Ü¹é ³»¼º
  • airway resistance
    ±âµµ ÀúÇ×
  • androgen resistance syndrome
    ³²¼º È£¸£¸ó ³»¼º ÁõÈıº, ³²¼º È£¸£¸ó ÀúÇ× ÁõÈıº
  • capillary resistance test
    ¸ð¼¼Ç÷°ü ÀúÇ×¼º ½ÃÇè
  • corrosion resistance
    ³»½Ä¼º, ºÎ½Ä ³»¼º
  • drug resistance factor
    ¾àÁ¦ ³»¼º ÀÎÀÚ
  • drug resistance transfer factor
    ¾àÁ¦ ³»¼º Àü´Þ ÀÎÀÚ
  • flow resistance
    È帧 ÀúÇ×, À¯·® ÀúÇ×
  • hepatic vascular resistance
    °£ Ç÷°ü ÀúÇ×
  • immunological resistance
    ¸é¿ª ÀúÇ×
  • magnetic resistance
    ÀÚ±â ÀúÇ×
  • multiple drug resistance gene
    º¹ÇÕ ¾àÁ¦ ³»¼º À¯ÀüÀÚ
  • peripheral resistance unit
    ¸»ÃÊ ÀúÇ× ´ÜÀ§
  • platinum resistance furnace
    Àü±â ¼Ò¼º·Î, ¹é±Ý ·Î
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
residual schizophrenia Blunted or inappropriate affect, social withdrawal, eccentric behaviour, or loose associations, but without prominent psychotic symptoms, as the remains of former psychotic symptoms of schizophrenia.
(05 Mar 2000)
residual urine Urine remaining in the bladder at the end of micturition in cases of prostatic obstruction, bladder atony, etc.
(05 Mar 2000)
residual volume The volume of air remaining in the lungs at the end of a maximal expiration. Common abbreviation is rv.
(12 Dec 1998)
neoplasm, residual Remnant of a tumour or cancer after primary, potentially curative therapy. (dr. Daniel masys, written communication)
(12 Dec 1998)
functional residual air The volume of air remaining in the lungs at the end of a normal, quiet expiration. It is the sum of the residual volume and the expiratory reserve volume. Common abbreviation is frc.
(12 Dec 1998)
functional residual capacity The volume of air remaining in the lungs at the end of a normal, quiet expiration. It is the sum of the residual volume and the expiratory reserve volume. Common abbreviation is frc.
(12 Dec 1998)
airway resistance The opposition of the tracheobronchial tree to air flow: the mouth-to-alveoli pressure difference divided by the air flow.
(12 Dec 1998)
ampicillin resistance Nonsusceptibility of a microbe to the action of ampicillin, a penicillin derivative that interferes with cell wall synthesis.
(12 Dec 1998)
androgen resistance syndromes A class of disorders associated with 5a-steroid reductase deficiency, testicular feminization, and related disorders.
Compare: steroid 5a-reductase, Reifenstein's syndrome, infertile male syndrome, testicular feminization syndrome.
(05 Mar 2000)
antibiotic resistance The ability of a bacterium tosynthesise a protein that neutralises an antibiotic.
(09 Oct 1997)
antibiotic resistance gene Genes in a microorganism which confer resistance to antibiotics, for example by coding for enzymes which destroy it, by coding for surface proteins which prevent it from entering the microorganism, or by being a mutant form of the antibiotic's target so that it can ignore it.
(09 Oct 1997)
bacteriophage resistance Resistance of a bacterial mutant to infection by a bacteriophage to which the parent (wild type) strain is susceptible.
(05 Mar 2000)
beta-lactam resistance Nonsusceptibility of an organism to the action of the beta-lactam antibiotics.
(12 Dec 1998)
capillary resistance The resistance offered to the flow of blood through the capillary portion of the peripheral vascular bed.
(12 Dec 1998)
capillary resistance test A tourniquet test used to determine presence of vitamin C deficiency or thrombocytopenia; a circle 2.5 cm in diameter, the upper edge of which is 4 cm below the crease of the elbow, is drawn on the inner aspect of the forearm, pressure midway between the systolic and diastolic blood pressure is applied above the elbow for 15 minutes, and a count of petechiae within the circle is made: 10, normal; 10 to 20, marginal zone; over 20, abnormal.
See: Rumpel-Leede test.
Synonym: capillary resistance test, vitamin C test.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • residual oil
    ÀÜÀ¯(¿øÀ¯¸¦ Á¤Á¦ÇÑ ÈÄ¿¡ ³²Àº ¿ÀÀÏ)
  • residual power
    Á¤ºÎÀÇ ÀÜ¿© ±ÇÇÑ
  • residual product
    ÀÜ¿© »ý»ê¹°;ºÎ»ê¹°
  • residual property
    ÀÜ¿© Àç»ê
  • residual radiation
    ÀÜ·ù¹æ»ç¼±
  • residual ray
    ÀÜ·ù¼±
  • residual security
    ÀÜ¿© Áõ±Ç(º¸Åë ÁÖ³ª Àüȯ »çä)
  • residual sovereignty
    ÀáÀç ÁÖ±Ç
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á